The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Choosing between equal and cap weight depends on goals and risk tolerance. This quick guide compares the two for retirement suitability.
24,468 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Pfizer stock is navigating a pivot from COVID-era revenues to a broader drug portfolio. Analysts weigh the odds of a ...
The USDA has expanded a Trader Joe's recall to nearly pounds frozen fried rice, now covering close to 10 million poun...
When high-level insiders transact, it sparks questions. This article explains what medical's general counsel sells si...
Intel kicked off a high-volume enterprise processor launch, lifting the stock as investors weigh the company’s path b...
A new Pew study shows half u.s. adults under 50 seek health guidance from social media influencers rather than doctor...
Barclays slashed Molson Coors' price target to $40, underscoring earnings headwinds as the brewer anticipates a tough...
David Tepper accelerates a $400 million macro bet pairing a country ETF with a memory-chip giant, underscoring what s...
Condo financing faces new insurance hurdles as lenders adjust rules; affordability hinges on policy shifts and region...
A new ETF strategy shifts focus from AI chipmakers to the data-center buildout, charging 0.47% and backing the compan...
BTIG raises Palo Alto Networks' price target to $216 after channel checks show improving partner feedback. Buy rating...
A COO selling stock may raise questions for investors, but one transaction rarely tells the whole story. This guide b...